Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Stellar Biotechnologies Appoints Two Members to SAB

Published: Saturday, June 07, 2014
Last Updated: Saturday, June 07, 2014
Bookmark and Share
Appointment of Gregory T. Baxter and Charles V. Olson to the Company's Scientific Advisory Board.

Stellar Biotechnologies, Inc. has announced the appointment of Gregory T. Baxter, Ph.D. and Charles V. Olson, D.Sc. to the Company's Scientific Advisory Board (SAB). They will join Daniel C. Adelman, M.D., Malcolm Gefter, Ph.D., Daniel Morse, Ph.D. and Andrew Saxon, M.D. on the SAB.

Stellar's SAB is composed of eminent scientists and physicians representing a range of disciplines including immunology, molecular biology and biochemistry. The SAB will be an ongoing resource to provide Stellar's management with counsel and guidance pertaining to the research, development, and clinical application of Stellar's KLH technology.

Dr. Gregory Baxter, a member of Stellar's Board of Directors since August 2012, is a Senior Scientist in the Department of Clinical Drug Development for CCS Associates, Inc. He also serves as Adjunct Associate Professor at Cornell University in the College of Chemical Engineering and on the Founders Board of Stanford University's StartX Med Program.

Dr. Baxter's background spans both science and business arenas including Program Director for the National Science Foundation (NSF) Division of Industrial Innovation and Partnerships; Founder and CSO of Hurel Corporation; Founder and CEO of Aegen Biosciences; and Research Scientists for Molecular Devices Corporation. Dr. Baxter received his Ph.D. in Biochemistry/Molecular Biology from the University of California, Santa Barbara.

"It's been gratifying to be a part of Stellar's corporate achievements this past year and I look forward to contributing on the Company's research front and in the advancement of its C. diff immunotherapy program," said Dr. Baxter.

Dr. Charles Olson is a biotechnology industry professional with broad scientific and operational experience, and specialization in manufacturing operations and process development. Dr. Olson currently serves as Vice President of CMC and Technical Operations for NGM Biopharmaceuticals and Vice President of Protein Sciences for Anthera Pharmaceuticals.

His background includes the positions of Senior VP of Product Development and Operations for Nexbio Inc.; VP of Hayward Operations for Cell Genesys; Senior Director of Manufacturing, Facilities and Process Development for Biomarin Pharmaceuticals; and Director of Manufacturing Sciences for Onyx Pharmaceuticals. Dr. Olson received his D.Sc. in Biochemistry from Hawthorne University.

"This is an exciting time for Stellar with its many promising commercial opportunities that the Company has in its sights," said Dr. Olson. "I am excited to join a team with such a strong technology position, and I look forward to being a part of their success."

Frank Oakes, Stellar's president and CEO, said, "We are delighted to have both of these biotechnology experts available to our internal teams and to advise our Board of Directors as we advance corporate objectives and deliver on key research and operational goals."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Stellar Signs Collaboration Agreement to Expand KLH Aquaculture Operations
Stellar secures strategic site in Mexico for exclusive sustainable KLH production.
Wednesday, August 12, 2015
Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship
Companies sign KLH supply agreement for Neovacs' Kinoid clinical trials and initial commercialization.
Saturday, April 04, 2015
Stellar and Araclon Biotech Sign Exclusive KLH Supply Agreement
Exclusive supply agreement for clinical trials in Alzheimer's active immunotherapies.
Wednesday, November 12, 2014
Stellar and Biovest Sign KLH Supply Agreement
Agreement for BiovaxID immunotherapy for follicular non-Hodgkin's lymphoma.
Tuesday, November 04, 2014
Stellar Biotechnologies Launches New Corporate Website
The new website showcases Stellar's Core KLH products, breakthroughs in aquaculture science, and strategic expansion of its immunotherapy program in a user-friendly platform.
Thursday, May 08, 2014
Stellar Issues Year-End Results and Highlights from 2013
Company announces financial results and operational highlights for 2013.
Friday, January 03, 2014
Stellar Announces Collaboration with Amaran Biotechnology, Inc.
Collaboration agreement to develop and evaluate methods for the manufacture of OBI-822 active immunotherapy.
Friday, December 13, 2013
Stellar Announces Issuance of Patents for C. diff Immunotherapy Technology
Issuance of two additional patents in U.S. and China.
Tuesday, December 10, 2013
Stellar Expands Senior Leadership Roles with Two Key Appointments
Appointment of Kathi Niffenegger and Catherine Brisson as CFO and COO respectively.
Wednesday, November 06, 2013
Stellar Presents Preclinical Poster on C. diff Active Immunotherapy
Poster presented at 7th Vaccine and ISV Congress being held in Spain.
Tuesday, October 29, 2013
Stellar’s Immunotherapy Technology Demonstrates Protection Against C. diff Infection
Study results presented this week at ClostPath 8 in Australia, October 22-26, 2013.
Tuesday, October 22, 2013
Stellar Appoints Tessie Che, Ph.D. to Board of Directors
Dr. Che is currently Chair of the Board of Directors of Amaran Biotechnology.
Thursday, September 26, 2013
Stellar Acquires Exclusive, Worldwide License to C. diff Immunotherapy Technology
Stellar expands with proprietary KLH-based vaccine program.
Wednesday, July 31, 2013
Stellar Biotechnologies Exceeds Aquaculture Capacity Goals
Facility expansion and cultivation innovations ensure supply leadership.
Tuesday, July 23, 2013
Stellar Biotechnologies & Life Diagnostics Announce Agreement for Stellar Brand KLH ELISA Test Kits
Company to utilize Stellar’s high-quality KLH to develop and manufacture Stellar brand KLH ELISA test kits for the detection of anti-KLH antibodies.
Thursday, October 27, 2011
Scientific News
Health Risks of Saturated Fats Aggravated by Immune Response
Research shows that the presence of saturated fats resulted in monocytes migrating into the tissues of vital organs.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
New Strategy for Combating Adenoviruses
Using an animal model they developed, Saint Louis University and Utah State university researchers have identified a strategy that could keep a common group of viruses called adenoviruses from replicating and causing sickness in humans.
Major Advance Toward More Effective, Long-Lasting Flu Vaccine
Collaboration shows vaccine candidate can produce powerful ‘broadly neutralizing antibodies’ in animal models.
Immune System: Help for Killer Cells
A study from the University of Bonn may show the way to more effective vaccines.
Protein Found to Control Inflammatory Response
A new Northwestern Medicine study shows that a protein called POP1 prevents severe inflammation and, potentially, diseases caused by excessive inflammatory responses.
A Leap Forward in Vaccinating Against HIV
A team of scientists has developed an experimental vaccine candidate that successfully stimulates the immune system activity in animal models necessary to stop HIV infection.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!